UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 17, 2018

Axovant Sciences Ltd.
(Exact name of registrant as specified in its charter)

Bermuda
 
001-37418
 
98-1333697
(State or other jurisdiction of
incorporation)
 
(Commission File No.)
 
(I.R.S. Employer Identification No.)

 
Suite 1, 3rd Floor
11-12 St. James's Square London SW1Y 4LB, United Kingdom
 
Not Applicable
 
 
(Address of principal executive office)
 
(Zip Code)
 

Registrant’s telephone number, including area code:  +44 203 318 9708


(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 5.07 Submission of Matters to a Vote of Security Holders.

On August 17, 2018, Axovant Sciences Ltd. (the “Company”) held its 2018 Annual General Meeting of Shareholders (the “Annual Meeting”) in London, United Kingdom. At the Annual Meeting, the shareholders considered and approved two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 24, 2018.

Of the 107,795,074 common shares outstanding as of the record date, 100,375,824 shares, or 93.1%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Annual Meeting.
 
Proposal No. 1: Vivek Ramaswamy, Roger Jeffs, Ph.D., George Bickerstaff, Atul Pande, M.D., Berndt Modig and Ilan Oren were elected to serve as directors until the Company’s 2019 Annual General Meeting of Shareholders and until their successors are duly elected, by the following votes:
 
Name
 
Votes For
 
Votes Against
 
Abstain
 
Broker Non-Votes
Vivek Ramaswamy
 
81,732,032

 
237,241

 
35,808

 
18,370,743

Roger Jeffs, Ph.D.
 
80,848,669

 
1,122,391

 
34,021

 
18,370,743

George Bickerstaff
 
81,807,904

 
160,515

 
36,662

 
18,370,743

Atul Pande, M.D.
 
79,093,440

 
2,875,555

 
36,086

 
18,370,743

Berndt Modig
 
79,087,032

 
2,880,048

 
38,001

 
18,370,743

Ilan Oren
 
79,079,705

 
2,887,462

 
37,914

 
18,370,743

 
Proposal No. 2: The shareholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending March 31, 2019, appointed Ernst & Young LLP as the Company's auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the Company's fiscal year ending March 31, 2019 and authorized the Company's Board of Directors, through the Audit Committee, to set the remuneration for Ernst & Young LLP as the Company's auditor for the Company's fiscal year ending March 31, 2019, by the following votes:
 
Votes For
 
Votes Against
 
Abstain
99,231,879

 
741,788

 
402,157








SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
Axovant Sciences Ltd.
 
 
 
 
Date: August 17, 2018
 
By:
/s/ Gregory Weinhoff
 
 
Name:
Gregory Weinhoff
 
 
Title:
Principal Financial Officer